The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications.
V. J. Sinibaldi
No relevant relationships to disclose
P. Huang
No relevant relationships to disclose
E. S. Antonarakis
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose
S. R. Denmeade
No relevant relationships to disclose
J. J. Kim
No relevant relationships to disclose
M. A. Eisenberger
No relevant relationships to disclose
D. Keizman
No relevant relationships to disclose